Cyclerion Therapeutics (CYCN) EBITDA Margin (2019 - 2025)
Cyclerion Therapeutics (CYCN) posted EBITDA Margin of 114.97% for Q3 2025, up 93.61% on a QoQ basis from 1797.85% in Q2 2025, and up 46647.0% year-over-year from N/an in Q3 2024.
Powered by 
Analysis
Cyclerion Therapeutics (CYCN) EBITDA Margin (2019 - 2025) Analysis & Trends
Cyclerion Therapeutics has reported EBITDA Margin for 6 years, with the latest figure at 114.97% in Q3 2025.
- On a quarterly basis, EBITDA Margin rose 46647.0% year-over-year to 114.97% in Q3 2025; TTM through Sep 2025 was 127.25%, a 292687.0% increase from a year earlier, with the FY2024 full-year figure at 181.4%, changed N/A from the prior year.
- EBITDA Margin was 114.97% for Q3 2025 at Cyclerion Therapeutics, up from 1797.85% in the prior quarter.
- The five-year high for EBITDA Margin was 27.8% in Q4 2024, with the low at 21604.84% in Q1 2021.
- Average EBITDA Margin over 4 years is 3505.29%, with a median of 1798.77% recorded in 2025.
- The sharpest annual moves came in 2021 and 2022: EBITDA Margin tumbled 1957437 bps in 2021, then surged 1977868 bps in 2022.
- Over 4 years, EBITDA Margin stood at 2690.06% in 2021, then slumped by 63 bps to 4389.87% in 2022, then jumped by 101 bps to 27.8% in 2024, then slumped by 514 bps to 114.97% in 2025.
- The last three EBITDA Margin figures came in at 114.97% (Q3 2025), 1797.85% (Q2 2025), and 1798.77% (Q1 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 34.95% |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -133.21% |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 37.40% |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 30.15% |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 32.54% |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -562.07% |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 17.93% |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | -23.56% |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -25,380.93% |
| 10 | Cyclerion Therapeutics | 15.70 Mn | 12.46 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | -114.97% |
| Jun 30, 2025 | -1,797.85% |
| Mar 31, 2025 | -1,798.77% |
| Dec 31, 2024 | 27.80% |
| Sep 30, 2024 | -581.44% |
| Jun 30, 2022 | -4,389.87% |
| Mar 31, 2022 | -1,826.16% |
| Dec 31, 2021 | -2,690.06% |
| Sep 30, 2021 | -3,242.82% |
| Jun 30, 2021 | -539.20% |
| Mar 31, 2021 | -21,604.84% |
| Dec 31, 2020 | -14,454.14% |
| Sep 30, 2020 | -5,445.00% |
| Jun 30, 2020 | -2,626.44% |
| Mar 31, 2020 | -2,030.47% |
| Dec 31, 2019 | -1,795.14% |
| Sep 30, 2019 | -2,004.01% |
| Jun 30, 2019 | -2,030.34% |